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Several studies have demonstrated that piperacillin/tazobactam produces a false-positive
result  for the galactomannan antigen test. However, the most recent literature has demon-
strated  that this interaction is no longer a concern. There is little information regarding
the  drug–laboratory interaction with the generics of piperacillin/tazobactam or other
broad-spectrum  beta-lactams, such as ceftaroline, doripenem, imipenem/cilastatin, and
meropenem.  The purpose of this study was to determine if a drug–laboratory interaction
exists  with these antibiotics. Tests showed that one lot of imipenem/cilastatin by Hospira
Healthcare  India Private Limited produced a false-positive result for the galactomannan
antigen  test. All other medications tested, including piperacillin/tazobactam from seven
manufacturers  and imipenem/cilastatin by Hospira Inc., did not produce positive results.
Since  the reason for this drug–laboratory interaction with imipenem/cilastatin is unknown,
more  studies are needed to further investigate this interaction. Providers also should be
educated  of these ﬁndings: no drug–laboratory interaction with piperacillin/tazobactam anda possible drug–laboratory interaction with imipenem/cilastatin (Hospira Healthcare India
Private Limited).
© 2014 Elsevier Editora Ltda. Este é um artigo Open Access sob a licença de CC BY-NC-NDPatients with invasive Aspergillus infections have a high
mortality  rate; therefore, early diagnosis is important. The
galactomannan antigen test, marketed as the PlateliaTM
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Aspergillus Ag (Bio-Rad), is a noninvasive tool used with
other  diagnostic tests for the early identiﬁcation of inva-
sive  Aspergillus infections. This antigen test works through
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etection of galactomannan, an antigen found in the cell
all  of Aspergillus species.1 Limitations of this test include
ow  sensitivity (50–80%) and cross-reaction with other fungi
e.g.,  Penicillium species, Histoplasma species, and Blastomyces
pecies).1,2
Certain penicillin antibiotics have been reported to produce
 false-positive galactomannan test, likely because they are
erived  from Penicillium species. Although a few reports have
hown  that the intravenous formulations of amoxicillin and
moxicillin/clavulanate (not available in the United States)
roduce  a false-positive result for the galactomannan antigen
est,1,3,4 most of the data demonstrating this drug–laboratory
nteraction is with brand name piperacillin/tazobactam
Zosyn®, Wyeth).1,3,5–12 In addition, researchers have found
hat  the degree of positivity varies among batches of
iperacillin/tazobactam and is dependent upon the time of
he  phlebotomy.5,7–9,11–13 Most of these in vitro and in vivo stud-
es  were  conducted prior to September 2009, when generic
iperacillin/tazobactam became available.14 As a result, little
nformation  is available regarding the drug–laboratory inter-
ction  with the generic versions of piperacillin/tazobactam
nd other broad-spectrum antibiotics. These broad-spectrum
ntibiotics are often used to empirically treat immunocompro-
ised patients, the population in which this galactomannan
ntigen test is most commonly performed. Because positive
alactomannan antigen tests may  result in the overtreatment
f  these patients, broad-spectrum antibiotics should be tested
or  this interaction.
The  aim of this study was  to screen whether the six generic
rands  of piperacillin/tazobactam that are available in the
nited  States, as well as other broad-spectrum beta-lactam
ntibiotics, produce a false-positive result for the galactoman-
an  antigen test.
A  vial of each antibiotic of interest available in the United
tates  was  obtained from the manufacturers, and pure chem-
cal  powders were  ordered for comparison. Pure piperacillin
nd  tazobactam powders were  included in this study to
nvestigate whether this interaction is due to the chemi-
al  itself or related to manufacturing processes. Antibiotics
ested included piperacillin [pure chemical, Tokyo Chemical
ndustry (Lot IK2QM-BM, Exp NA)], tazobactam [pure chem-
cal,  Chem-Impex Int’l (Lot TB00N110629, Exp 6/28/2014)],
iperacillin/tazobactam [Zosyn®, Wyeth (Lot AH1C/11, Exp
/2015);  six generics: Apotex (Lot 500C003, Exp 1/2014), APP
Lot  2C08TN, Exp 2/2015), Auromedics (Lot PT0212001-A,
xp 2/2014), Hospira (Lot 110278M, Exp 11/1/2013), Sagent
Lot  PT0211008-A, Exp 8/2013), and Sandoz (Lot BY0110,
xp  9/2013)], imipenem/cilastatin [Primaxin®, Merck (Lot
007317,  Exp 3/2014); two generics, APP (Lot 0013D21, Exp
/2014)  and Hospira (Batch 1, Lot 613C015, Exp 12/2013;
atch 2, Lot 613C025, Exp 8/2013)], meropenem [Merrem®,
straZeneca  (Lot JX109, Exp 2/2015)], doripenem [Doribax®,
rtho-McNeil  (Lot ALZT600, Exp 11/2013)], and ceftaroline
TeﬂaroTM, Forest (Lot 0012D16, Exp 11/2013)]. Antibiotic pow-
ers  were  measured and divided into aliquots representing the
econstituted  concentration per the manufacturers’ package
nserts  when 1 mL  of diluent was  added (i.e., 225 mg/mL
f  piperacillin/tazobactam, 50 mg/mL  of imipenem/cilastatin,
0 mg/mL  of meropenem, 50 mg/mL  of doripenem, and
0  mg/mL  of ceftaroline).4;1 8(5):544–547  545
Presence of the interaction was  tested utilizing the
PlateliaTM Aspergillus Ag (Bio-Rad) kit (Kit 1, Prod# 62793, Lot
9J0030,  Exp 11/30/2010; Kit 2, Prod# 62794, Lot 2F0017, Exp
6/5/2013)  according to standard methods. Two kits were  uti-
lized  for this study; one expired kit was  used for a practice run
while  the results of this study were  produced and reported
using  the in-date kit. All tests were run in quadruplicate
between December 2012 and April 2013. For any medication
with  a positive initial result, four dilutions were  subsequently
tested to mimic  drug concentrations in the body. Dilutions
included the average peak serum concentration in the body
according  to the manufacturers’ package inserts plus one
dilution  above and two dilutions below that concentration.
Dilutions were ﬁrst tested in normal saline and then in human
serum  (drawn from the principle investigator). Antibiotics
were  diluted in serum to evaluate the drug–laboratory inter-
action  in a clinical sample.
Imipenem/cilastatin by Hospira was  the only medi-
cation that produced a positive galactomannan antigen
test.  All other reconstituted medications tested (including
imipenem/cilastatin from two other manufacturers) did not
produce  a positive result. For imipenem/cilastatin by Hospira,
the  reconstituted medication (i.e., 50 mg/mL), four dilutions
in  normal saline (i.e., 10, 20, 40, and 80 mcg/mL), and four
dilutions in human serum (i.e., 10, 20, 40, and 80 mcg/mL) pro-
duced  positive antigen tests. The optical density (OD) indices
of  the reconstituted medication were 2.96 and 2.97. Similar
results  were found with the four dilutions in both normal
saline  and human serum (Table 1), and when utilizing both
galactomannan antigen kits. When testing a second batch
of  imipenem/cilastatin by Hospira (i.e., the same medication
with  a different lot number), the reconstituted medication
and  four dilutions in normal saline tested negative (i.e., OD
indices  < 0.5). The four dilutions of the second batch were not
tested  in human serum since the four dilutions in normal
saline  were negative.
To  the best of our knowledge, this is the ﬁrst study evalu-
ating  the drug–laboratory interaction among the six generics
of  piperacillin/tazobactam available in the United States and
other  broad-spectrum antibiotics. All piperacillin/tazobactam
brands produced negative results with the galactomannan
antigen test in this study, which is consistent with the most
recent  data regarding this drug–laboratory interaction. Xavier
et  al.15 conducted an in vitro study in Brazil that investigated
the drug–laboratory interaction with the brand and four gener-
ics  of piperacillin/tazobactam available in Brazil at that time.
When  testing the concentrated medications (i.e., 45 mg/mL),
only  one of the ﬁve brands of piperacillin/tazobactam pro-
duced  a positive galactomannan antigen test, showing this
drug–laboratory interaction to be manufacturer dependent.15
However, when testing the diluted medications (i.e., average
peak  serum concentration in the body, 300 mcg/mL; one dilu-
tion  above, 600 mcg/mL; and two dilutions below, 150 mcg/mL
and  75 mcg/mL), all concentrations produced a negative anti-
gen  test.15 These authors concluded that this drug–laboratory
interaction between piperacillin/tazobactam and the galac-
tomannan  antigen test was  no longer clinically relevant in
Brazil.15 Similarly, Mikulska et al.16 conducted a study in Italy
that  investigated the drug–laboratory interaction with brand
piperacillin/tazobactam (TazocinTM, Pﬁzer). When testing 90
546  b r a z j i n f e c t d i s . 2 0 1 4;1  8(5):544–547
Table 1 – Positive results: optical density indices of dilutions.
Concentration of imipenem/cilastatin (mcg/mL) In normal saline In human serum
OD for Well 1 OD for Well 2 OD for Well 1 OD for Well 2
80 6.11 5.88 4.96 5.10
40 1.58 1.74 3.23 3.34
20  0.64 0.80 1.78  1.78
10 0.61 0.61 1.13 1.03
r
5.  Adam O, Aupérin A, Wilquin F, et al. Treatment withOD, optical density.
randomly selected vials of piperacillin/tazobactam, none pro-
duced a positive antigen test.16 When testing patients’ serum,
the  antigen test was  positive in slightly more  serum samples
from  patients receiving piperacillin/tazobactam than those
patients  who  did not, which was  not found to be statistically
signiﬁcant (2.5% vs. 1.6%; p = 0.18).16 These authors con-
cluded that brand piperacillin/tazobactam no longer produces
a  false-positive result for the galactomannan antigen test;
however,  there is a concern with the multiple generics that are
available.16 Based on our study, the drug–laboratory interac-
tion  with the six generics of piperacillin/tazobactam available
in  the United States revealed no positive results. Researchers
have  speculated that the reason for this drug–laboratory
interaction no longer existing is secondary to changing
manufacturing processes.8,17 Based on the package insert
information, the brand name product was  reformulated in
2005  from containing no excipients or preservatives to con-
taining  edetate disodium dehydrate and sodium citrate.18
This study did ﬁnd that imipenem/cilastatin by Hospira
Healthcare India Private Limited, a subsidiary of Hospira
Inc.,  produced a positive antigen test. This ﬁnding is puz-
zling  especially since imipenem/cilastatin is derived from
a  bacterium Streptomyces cattleya and, therefore, does not
contain  galactomannan and should not produce a positive
galactomannan antigen test. More  speciﬁcally, two batches
of  imipenem/cilastatin manufactured by Hospira were tested
that  produced conﬂicting results. In comparison of these
two  vials of imipenem/cilastatin, both batches had similar
National  Drug Code (NDC) numbers (i.e., same manufac-
turer, same medication, and different package size), different
lot  numbers, and different expiration dates. Batch 1 that
produced  a positive antigen test was  manufactured by Hos-
pira  Healthcare India Private Limited (Chennai, India) while
Batch  2 that tested negative was  manufactured by Hospira,
Inc.  (Lake Forest, Illinois). The reason for these conﬂicting
results remains unknown but may  possibly be due to differing
manufacturing processes between the two locations. Because
positive  results were  seen with only one manufacturer, this
observation  may  not be generalizable to imipenem/cilastatin
as a whole.
Although this study reports in vitro data of limited
scope, there are important clinical implications. Results
suggest there is no longer a drug–laboratory interaction
between piperacillin/tazobactam and the galactomannan
antigen test, but there is a possible drug–laboratory interaction
with  imipenem/cilastatin (Hospira Healthcare India Private
Limited).  Knowing which medications produce a false-positive
result  for the galactomannan test is important since theresults of this test may  affect the treatment of patients result-
ing  in unnecessary treatment, increased healthcare costs, risk
of  adverse effects, and drug–drug interactions.
Our study has several limitations. This study was  an in vitro
study,  and not all in vitro data correlate with in vivo data.
However, clinical samples were tested (i.e., four dilutions in
serum)  once the medication produced a positive result in nor-
mal  saline. A single vial of each medication (i.e., one batch)
was  used in this study, which may  not be generalizable to every
manufacturer  or lot. Lastly, only one in-date Platelia Aspergillus
Ag  kit was used for this study; thus, the number of tests that
were  run was  limited.
In  conclusion, this in vitro study suggests that
imipenem/cilastatin by Hospira Healthcare India Private
Limited  produces a false-positive result for the galactoman-
nan  antigen test in at least some lots. Since the mechanism
of  this drug–laboratory interaction is unknown, this inter-
action  should be further investigated with more  in vitro
studies  testing additional batches of imipenem/cilastatin by
Hospira Healthcare India Private Limited and in vivo studies
testing  patients’ serum who are receiving this medication.
In  addition, provider education will be necessary in order to
ensure  effective diagnoses and patient care in patients with
suspected  Aspergillus infections.
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